Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Income from Continuing Operations (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Income from Continuing Operations for 14 consecutive years, with 11938000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 46.44% year-over-year to 11938000.0, compared with a TTM value of 71425000.0 through Dec 2025, up 31.8%, and an annual FY2025 reading of 81777000.0, up 29.41% over the prior year.
  • Income from Continuing Operations was 11938000.0 for Q4 2025 at Enanta Pharmaceuticals, up from 18588000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 11938000.0 in Q4 2025 and bottomed at 81903000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 29530400.0, with a median of 27499000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations plummeted 267.11% in 2021, then soared 67.81% in 2022.
  • Year by year, Income from Continuing Operations stood at 30115000.0 in 2021, then increased by 3.75% to 28986000.0 in 2022, then dropped by 15.25% to 33407000.0 in 2023, then skyrocketed by 33.28% to 22290000.0 in 2024, then skyrocketed by 46.44% to 11938000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ENTA at 11938000.0 in Q4 2025, 18588000.0 in Q3 2025, and 18255000.0 in Q2 2025.